

## Disclosures

### Personal Commercial (9)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amgen	Research/Research Grants	Significant (>= \$5,000)	Acute Coronary Syndromes
Boehringer Ingelheim Pharmaceuticals, Inc	Research/Research Grants	Significant (>= \$5,000)	Acute Coronary Syndromes
Bristol-Myers Squibb Company	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
CSL Behring	Research/Research Grants	Significant (>= \$5,000)	Acute Coronary Syndromes
Edwards Lifesciences	Consultant Fees/Honoraria	Significant (>= \$5,000)	Valvular Heart Disease
Eli Lilly and Company	Research/Research Grants	Significant (>= \$5,000)	Acute Coronary Syndromes
National Comprehensive Cancer Center	Consultant Fees/Honoraria	Modest (< \$5,000)	Other
Xencor	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Zoll Medical	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
National Comprehensive Cancer Network † National Comprehensive Cancer Network	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 7/26/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### Confidentiality, Disclosure and Assignment Agreement | Signed on 7/26/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### Embargo | Signed on 7/26/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

### On-Going Obligation Agreement | Signed on 7/26/2024

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.